探索治疗对GLP-1受体激动剂的治疗反应的预测因素,以戒烟
Luba Yammine1, Constanza de Dios2, Robert Suchting3
1Associate Professor, Louis A. Faillace, M.D., Department of Psychiatry and Behavioral Sciences, The University of Texas Health Science Center at Houston (UTHealth), McGovern Medical School, 1941 East Road, BBSB, Houston, TX.
概括
结合尼古丁贴片的exenatide可以改善每天吸烟超过20支烟的人的戒烟,没有糖尿病前期或肥胖,并且抑郁症最小. 遗传因素也影响了埃克西纳提德的产生.
科学领域:
- 药理学 药理学是指药理学的学科.
- 成 药物 药物 药物 药物
- 遗传学 遗传学 是一个
背景情况:
- 了解戒烟药物疗效的预测因素对于提高治疗效果至关重要.
- 一项试点试验表明,当与尼古丁贴片一起使用的exenatide,一种类似葡萄糖类-1受体激动剂,与单独使用尼古丁贴片相比,改善了吸烟禁欲.
- 这次二次分析调查了基线特征,这些特征可能预测了对exenatide的差异性治疗反应.
研究的目的:
- 为了探索潜在的基线患者特征与异性治疗反应与exenatide作为尼古丁贴片的辅助,以戒烟.
- 为了确定吸烟者的子组,这些人可能会从埃克森治疗中获益更多.
主要方法:
- 一项随机对照试验的二次分析,该试验涉及84名糖尿病前期和/或超重的吸烟者.
- 参与者接受了尼古丁贴片和简短的咨询,随机分配到安慰剂或exenatide (每周2毫克).
- 贝叶斯通用线性建模被用来检查人口,心理,临床,吸烟相关和遗传因素对治疗反应的影响,后期概率≥75%,表明有影响的证据.
主要成果:
- 在参与者吸烟>20支/天 (PP=81.7%),没有糖尿病前期 (PP=76.0%) 和没有肥胖 (PP=94.4%) 的参与者中,纳提德的疗效更大.
- 在没有/最小抑郁症状的个体 (PP=91.2%) 中观察到有效性,但在有症状的人中没有.
- 在具有CHRNA rs16969968 GG基因型 (PP=88.6%) 的个体中,exenatide比安慰剂更有效.
结论:
- 埃塞纳提德在促进戒烟的有效性似乎受到每天吸烟的香烟数量,代谢状态 (糖尿病前期,肥胖),心理因素 (抑郁症症状) 和遗传因素 (CHRNA rs16969968基因型) 的缓解.
- 这些发现表明,个性化的戒烟治疗方法可能是有益的.
- 需要更大的前性研究来证实和扩展这些结果.
相关概念视频
Glucagon-like Receptor Agonists
295
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
295
Oral Hypoglycemic Agents: Biguanides and Glitazones
165
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
165
Oral Hypoglycemic Agents: Glinides
136
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
136
Dipeptidyl Peptidase 4 Inhibitors
166
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
166
Drugs Acting on Autonomic Ganglia: Stimulants
1.3K
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
1.3K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
152
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
152


